Randomized phase II study of axitinib versus standard of care in patients with recurrent glioblastoma

Authors :: Vincent Verschaeve
An Van Binst
Hendrik Everaert
F. Bouttens
Johnny Duerinck
Stephanie Du Four
Bart Neyns
Source :: Journal of Clinical Oncology. 32:2018-2018
Publication Year :: 2014
Publisher :: American Society of Clinical Oncology (ASCO), 2014.
Abstract: 2018 Background: Vascular endothelial growth factor receptor (VEGFR) signal transduction mediates glioblastoma (GB) associated neo-angiogenesis. Axitinib is an oral small molecule tyrosine kinase i...

Subjects :: Cancer Research
Standard of care
business.industry
Recurrent glioblastoma
Phases of clinical research
Small molecule
Axitinib
Oncology
Cancer research
Medicine
In patient
Signal transduction
business
Tyrosine kinase
medicine.drug

Full Text Access

Tools